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ABSTRACT 
 
 
Aim: Wolfram syndrome is a rare genetic defect in WFS1 or WSF2(CISD2). It includes 
diabetes mellitus and insipidis, sensorineural deafness, optic atrophy, but not bladder 
dysfunction. However, this has appeared a common finding in our national referral 
clinic, and we sought to quantify this problem. 
 
Methods: Data were collected from a multidisciplinary team managing all Wolfram 
patients in the UK. The following was analyzed: age, date of non-invasive urodynamics 
(NIU), symptoms, bladder capacity, voided volume, post-void residual and uroflow 
pattern. Bladder capacity was given as percentage predicted bladder capacity (PBC).  
Bladders were divided into normal, overactive (OAB), and underactive (UAB). 
Symptoms, bladder behavior, and genotyping were correlated. Data were expressed as 
median (interquartile range). 
 
Main results: Forty patients with Wolfram syndrome were identified, and 38 
underwent NIU. This showed normal bladder function (n= 4), OAB (n =9), UAB (n = 25). 
Symptoms were present in only 11 children. The different patterns of bladder behavior 
(OAB vs. normal vs. UAB) were significantly associated with different %PBC (36(29-
59)% vs. 105(93-233)% vs. 100(77.5-337)%; P<0.001), and percentage emptying 
(100(80-100)% vs. 100(87-100)% vs. 69(48-93)%; P<0.05). There was no association 
of genotype, symptoms and bladder behavior. Patients with megacystis were older: 
[13.4 (9.7-16.1) vs. 15.4(13.9-18.7) years;  P<0.05). 
 
Conclusion: Bladder dysfunction is very common in Wolfram syndrome (~90%), but 
most children cope (symptoms ~30%). With time there is a significant progression to 
megacystis, which may represent an underlying neuropathic myogenic failure and is 
likely to require intervention in the future. 
 
 
Keywords: Wolfram syndrome; bladder dysfunction; urodynamics; diabetes mellitus; 
diabetes insipidis; megacystis 
 
Level of Evidence: Level II (National cohort study of prognosis) 
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Introduction 
Wolfram syndrome is a rare genetic disorder comprising diabetes mellitus, diabetes 
insipidus, optic atrophy and sensorineural hearing loss.  It is also known by the acronym 
DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness).  Children 
present in early childhood with diabetes mellitus and then most often progress with 
optic atrophy characterized by initial loss of peripheral and colour vision, progressing to 
blindness (1).  Eventual neurological degeneration in early adulthood with ataxia and 
dysphagia followed by brainstem atrophy and central apnoea is common, and results in 
a reduced life expectancy. 
The genetic mutation for most patients with Wolfram syndrome is found in the WFS1 
locus (2) .  The inheritance pattern is usually autosomal recessive, but there are some 
dominant mutations reported (3), although dominant WFS1 mutations are also seen in 
patients with isolated low frequency sensorineural hearing loss, and occasionally those 
with isolated diabetes mellitus.  Some patients, mainly from the Middle East, have a 
mutation in the WFS2 (CISD2) gene (4). 
 
Bladder dysfunction and urological manifestations are commonly reported in Wolfram 
syndrome, although they are not officially part of the syndrome.  These include upper 
tract dilatation, megacystis or an overactive bladder (5).  The aetiology for this is 
unknown, however, it has been hypothesized to be due to either a stretch injury 
secondary to polyuria, or autonomic dysfunction. 
 
The aim of our study was to quantify the problem of bladder dysfunction in children 
with Wolfram syndrome and identify a correlation with the genotype. 
 
Methods 
Birmingham Children’s Hospital is a national referral centre for all patients diagnosed 
with Wolfram syndrome in the UK and runs a regular multidisciplinary clinic including a 
paediatric endocrinologist, ophthalmologist, neurologist and a paediatric urologist.  
Routinely, Wolfram patients would have non-invasive urodynamics (NIU) performed 
during their clinic review. 
 
A prospectively maintained database was used and interrogated for symptoms (e.g. 
incontinence, urgency and urinary tract infections), bladder capacity, voided volume, 
post-void residual and uroflow pattern.    
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Uroflow was measured using the Dantec Danflow 1000, and post-void residual was 
measured using the Ecoson bladder scanner. Bladder capacity was then calculated in 
milliliters as the volume voided added to the post void residual and then measured as a 
percentage of the predicted bladder capacity (PBC) (calculated using the formula [age in 
years+1)x30mls] (6). Uroflow was characterized as Normal (bell-shaped), Precipitous 
(Suggesting OAB), Staccato or Interrupted.  Maximum flow rate (Qmax) in ml/s was 
recorded and the predicted Qmax was taken as the square root of the volume voided (7). 
Precipitous uroflows had actual Qmax greater than 150% of the predicted value. 
 
Bladders were divided into normal, overactive (OAB), underactive (UAB) by pattern of 
the uroflow, (Figure 1).  Megacystis was defined as >150% of predicted bladder 
capacity.  Symptoms, bladder behavior and genotyping were correlated in each patient. 
Bladders were then compared by classification of behavior for capacity (given as 
percentage of predicted bladder capacity (%PBC) using the ICCS formula), voiding 
efficiency (defined as bladder volume-post void residual/bladder volume, normal 
>90%), ages of patients and presence of symptoms.  
 
Genotyping was performed by the NHS West Midlands Regional Genetics Laboratory. 
 
Data were expressed as median (interquartile range) unless otherwise indicated, and 
analyzed by Fisher exact test or Kruskal-Wallis test.  A P value of ≤0.05 was taken as 
significant.  
 
Results 
Of 40 Wolfram children seen in clinic, 38 had undergone NIU at a median age of 
14 (range 3.24-22.9) years. Normal bladder function was present in 4 (11%), 
with the remaining 34 (89%) having demonstrable bladder dysfunction.  This 
was characterized as an overactive (n=9) or underactive bladder (n = 25).  Only 
11 children were symptomatic by enquiry. 
  
There was no significant difference between the staccato and interrupted 
uroflow groups in terms of %PBC [98(83-193)% vs. 105(80-229)%] or voiding 
efficiency (%Emptying) [71(50-93)% vs. 62(38-81)%], so these were grouped 
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together as under active bladders (UAB). The different patterns of bladder 
behavior (OAB vs. normal vs. UAB) were significantly associated with different 
percentage of median predicted bladder capacity (%PBC) [36(29-59)% vs. 
105(93-233)% vs. 100(77.5-337)% ; P<0.001 (Figure 2A) and % emptying 
[100(80-100)% vs. 100(87-100)% vs. 69(48-93)% ; P<0.05] (Figure 2B).  
 
Genotype was available in 33 Wolfram patients, but did not correlate with 
bladder behavior or symptoms, (Table 1). 
 
Symptoms were recorded in 11 children with Wolfram syndrome (Table 2). 
There were no episodes of urinary tract infection. Daytime urinary incontinence 
was present in 7, and 3 further children were on clean intermittent 
catheterization (CIC) (Mitrofanoff, n=1 and urethral, n = 2). Diurnal incontinence 
(n= 3), or nocturia (n=1) were noted. Daytime frequency was present in 3 and 
urgency in 1. 3 suffered from nocturia. These symptoms did not correlate with 
age. There were no symptomatic patients in the normal uroflow group. 
Symptoms were noted in OAB (1/9), UAB staccato uroflow (7/17) and UAB 
interrupted uroflow (3/8) (P=0.05 Fisher exact test). 
 
Children with megacystis were significantly older than those without [13.4 (9.7-
16.1) years vs. 15.4 (13.9-18.7) years ; P<0.05] (Figure 2C). Similarly there was a 
significant age progression with different bladder behaviors: normal uroflow 
[10.0 (4.8-11.5) vs. OAB 13.5 (9.3-17.9) vs. staccato uroflow 13.9 (12.8-16.0) vs. 
interrupted uroflow 19.0 (15.1-21.0) years; P<0.001 (figure 2D). 
 
 
Discussion 
This study describes the bladder function in a national cohort of children and 
young adults with Wolfram syndrome. It suggests a progression of bladder 
dysfunction to megacystis as these patients age, together with an association 
between older age and change in pattern from normal, to UAB with staccato 
uroflow, then interrupted uroflow. 
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Bladder dysfunction in Wolfram syndrome is a common occurrence with most of 
our national cohort having some degree of bladder dysfunction and is consistent 
with other studies (5).  Strikingly, however, less than 30% were actually 
symptomatic and none showed any UTIs. This is surprising given the degree of 
objective bladder dysfunction. It may be that the polyuria seen in these patients 
is important in reducing their UTI risk. 
 
Overactive bladders were present in 25% and was the main feature of the 
urodynamic findings with significant reduction in their predicted bladder 
capacity. Most however emptied normally. Underactive bladders were 
significantly larger than the OAB, but had markedly reduced emptying efficiency. 
There was a significant age–related progression in bladder behaviour from 
normal through OAB to UAB with staccato uroflow, and finally UAB interrupted 
uroflow. This was mirrored by the older age of Wolfram patients with 
megacystis. This progression to ultimate atonia has been reported previously (8) 
. 
 
The aetiology for this bladder dysfunction may be a polyuric stretch injury, or 
autonomic nerve dysfunction. Polyuria due to diabetes insipidus and diabetes 
mellitus may result in a recurrent stretch injury to the bladder (9) (10). Acute 
over-distension due to post-operative urinary retention may cause ongoing 
problems due to a similar stretch injury to the bladder (11). This could suggest 
the use of desmopressin in Wolfram syndrome, not just to reduce urine output 
and improve continence, but also as a therapeutic intervention to reduce the 
progression of bladder dysfunction due to stretch injury associated with 
polyuria. Diabetic neuropathy causing bladder dysfunction has been well 
described, but generally occurs in patients >50 years of age (12). Wolfram 
syndrome patients are particularly susceptible to neuropathy. In those in whom 
electromyography has been reported, an axonal sensorineural polyneuropathy 
has been the predominant pattern (13) . 
 
As <30% of our cohort developed symptoms we feel it is a testament to their 
ability to cope with bladder dysfunction. But, it does also suggest a hidden 
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morbidity for the future. This study used non-invasive urodynamics to asses and 
monitor these patients. This has the advantages of being quick and non-invasive, 
but bladder compliance, detrusor overactivity or lack of contractility, and 
bladder neck function (or dysfunction) have not been measured. Staccato 
uroflows are typical of underactive bladder, and it is very likely that these have 
progressed with myogenic failure to in the interrupted pattern. Most patients 
have not had invasive urodynamics however (as they are asymptomatic), so this 
possibility of myogenic failure cannot be proven. It is possible that some of these 
Wolfram patients have a combination of OAB and detrusor sphincter dyssynergia 
(DSD). Detrusor pressure measurements or electromyography of the pelvic floor 
during voiding would be required to do this.  
 
Eventual progression to severe megacystis with upper tract dilatation requiring 
continent reconstruction (such as a Mitrofanoff) has been described (14) but was 
not a common outcome in our series.  
 
In conclusion, bladder dysfunction in children and young adults with Wolfram 
syndrome is common and progressive mandating the need for careful 
monitoring and urological follow-up, even in those who are asymptomatic.  
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Legends: 
 
Figure 1: Patterns of uroflow: Normal bell-shaped curve A,B. Precipitous 
uroflow typical of OAB, C,D. Staccato uroflow, typical of UAB, E,F. Interrupted 
uroflow which may be severe UAB or detrusor sphincter dyssynergia, G,H. 
 
Figure 2: Analysis of bladder function in Wolfram Syndrome:  Bladder capacity 
in Wolfram patients categorized by non-invasive urodynamics, A. Voiding 
efficiency measured by emptying post void expressed as a percentage of bladder 
capacity, (% emptying post void) B. Megacystis (>150% predicted bladder 
capacity (PBC)), C. Age comparison of Wolfram patients categorized by uroflow 
pattern, D. 
 
Table 1: Genetic mutations and the types of bladder dysfunction seen in 
Wolfram patients 
 
Table 2: Symptom patterns seen in the 11 symptomatic patients 
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Figure 1 
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Figure 2 
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Patient Nucleotide change 1 Protein 1 Nucleotide change 2 Protein 2 
Bladder 
Behaviour 
          
1 c.2051C>G p.Ala684Gly c.2051C>G   Overactive Bladder 
2 c.2099G>A p.Trp700* c.2099G>A p.Trp700* Overactive Bladder 
3 c.1338G>A   c.2327A>T p.Glu776Val Overactive Bladder 
4 
homozygous loss of 
function   
homozygous loss of 
function   Overactive Bladder 
5 
homozygous loss of 
function   
homozygous loss of 
function   Overactive Bladder 
6 loss of function   
no second mutation 
detected   Overactive Bladder 
7 missense change   
no second mutation 
detected   Overactive Bladder 
8 Not recorded       Overactive Bladder 
9 
homozygous loss of 
function  
homozygous loss of 
function  Normal 
10 
heterozygous loss of 
function  
heterozygous loss of 
function  Normal 
11 
homozygous loss of 
function  
homozygous loss of 
function  Normal 
12 c.2099G>A p.Trp700* c.2099G>A p.Trp700* Normal 
13 
heterozygous loss of 
function   
heterozygous loss of 
function   Underactive Bladder 
14 
homozygous loss of 
function    
homozygous loss of 
function    Underactive Bladder 
15 
homozygous loss of 
function    
homozygous loss of 
function    Underactive Bladder 
16 
homozygous loss of 
function    
homozygous loss of 
function    Underactive Bladder 
17 c.911_914dupTTGA       Underactive Bladder 
18 c.911_914dupTTGA       Underactive Bladder 
19 c.2206G>A p.Gly236Ser c.1049_1051delTCT p.Phe350del Underactive Bladder 
20 c.1549delC p.Arg57Alafs*5 c.2033G>A   Underactive Bladder 
21 c.1549delC p.Arg57Alafs*5 c.2033G>A   Underactive Bladder 
22 c.2099G>A p.Trp700* c.2099G>A p.Trp700* Underactive Bladder 
23 c.2648-2651delTCTT p.Phe883Serfs*68 c.2146G>A p.Ala715Thr Underactive Bladder 
24 c.2643_2646delCTTT p.Phe883Serfs*69 c.2643_2646delCTTT p.Phe883Serfs*69 Underactive Bladder 
25 
heterozygous loss of 
function   
heterozygous loss of 
function   Underactive Bladder 
26 
heterozygous loss of 
function   
heterozygous loss of 
function   Underactive Bladder 
27 
homozygous loss of 
function   
homozygous loss of 
function   Underactive Bladder 
28 
homozygous loss of 
function   
homozygous loss of 
function   Underactive Bladder 
29 
heterozygous loss of 
function   
heterozygous loss of 
function   Megacystis 
30 homozygous missense       Megacystis 
31 c.937C>T p.His313Tyr 
Exon 1 variant unknown 
significance   Megacystis 
32 
homozygous loss of 
function     
homozygous loss of 
function    Megacystis 
33 
homozygous loss of 
function     
homozygous loss of 
function    Megacystis 
 
 
Table 1: The genetic mutations and the types of bladder dysfunction seen in 
Wolfram patients 
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Incontinence Bladder dysfunction  
UTI 
  Day Night Day Night  
Y Y No No No 
Y Y . . . 
Y Y Frequency No No 
Y N No Nocturia No 
Y N No No No 
Y N . . . 
Y N No Nocturia  No 
N Y Urgency No No 
CIC Mitrofanoff Overnight Drainage Frequency No No 
CIC N . . . 
CIC N Frequency Nocturia No 
 
Table 2: Symptom patterns seen in the 11 symptomatic patients  
